Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 18/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24834529 | 0.83 | NLRP3 (0.52) | NLRP3KDM4EPOLBMAPTGAA | |
| SCHEMBL24834877 | 0.80 | NLRP3 (0.53) | NLRP3 | |
| SCHEMBL24076982 | 0.79 | NLRP3 (0.55) | NLRP3 | |
| SCHEMBL24077227 | 0.77 | NLRP3 (0.55) | NLRP3 | |
| SCHEMBL30168573 | 0.76 | NLRP3 (0.60) | NLRP3MAPT | |
| SCHEMBL24077213 | 0.76 | NLRP3 (0.60) | NLRP3MAPT | |
| SCHEMBL24077286 | 0.75 | NLRP3 (0.56) | NLRP3KDM4EPOLBMAPT | |
| SCHEMBL24077345 | 0.75 | NLRP3 (0.52) | NLRP3MAPT | |
| SCHEMBL30355036 | 0.75 | NLRP3 (0.40) | NLRP3KDM4EGAA | |
| SCHEMBL24077195 | 0.74 | NLRP3 (0.53) | NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043450-A1 | NEW COMPOUND | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-08 | — | — | US | disclosed |
| EP-4217347-A1 | NEW COMPOUNDS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
| CN-116194445-A | New compounds | 詹森药业有限公司 | 2023-05-30 | — | — | CN | disclosed |
| WO-2022063896-A1 | NEW COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043450-A1 | NEW COMPOUND | NLRP3, NLRP1, PYCARD | NLRP3 1/4885KDM4E 3649/4885POLB 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.